Analysts Have Mixed Ratings On Microsoft Corporation (MSFT), Novavax, Inc. (NVAX) - Financial Mercury

The shares of Microsoft Corporation (NASDAQ:MSFT) has been pegged with a rating of Buy by Mizuho in its latest research note that was published on March 14th, 2019. Mizuho wasnâ€™t the only research firm that published a report of Microsoft Corporation, with other equities research analysts also giving their opinion on the stock. Nomura advised investors in its research note published on January 31st, 2019, to Buy the MSFT stock while also putting a $113 price target. The stock had earned Neutral rating from Citigroup when it published its report on January 31st, 2019. That day the Citigroup set price target on the stock to $110. The stock was given Buy rating by BofA/Merrill in its report released on October 25th, 2018, the day when the price target on the stock was placed at $140. BofA/Merrill was of a view that MSFT is Buy in its latest report on October 22nd, 2018 while giving it a price target of $135. Wedbush thinks that MSFT is worth Outperform rating. This was contained in the firmâ€™s report on October 19th, 2018 in which the stockâ€™s price target was also moved to $140.

Amongst the analysts that rated the stock, 1 have recommended investors to sell it, 2 believe it has the potential for further growth, thus rating it as Hold while 18 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $127.59. The price of the stock the last time has raised by 34.88% from its Week high price while it is raised higher than its 52-Week low price. A look at the stockâ€™s other technical shows that its 14-day RSI now stands at 71.62.

The shares of the company added by 0.83% during the trading session on Wednesday, reaching a low of $120.54 while ending the day at $121.77. During the trading session, a total of 18.35 million shares were traded which represents a 29.58% incline from the average session volume which is 26.06M shares. MSFT had ended its last session trading at 120.77. Microsoft Corporation currently has a market cap of $930.12B, while its P/E ratio stands at 28.32, while its P/E earnings growth sits at 7.85, with a beta of 1.21. Microsoft Corporation debt-to-equity ratio currently stands at 0.85, while its quick ratio hovers at 3.10. MSFT 52-week low price stands at $90.28 while its 52-week high price is $121.65.

The company in its last quarterly report recorded $1.10 earnings per share which is above the $1.09 predicted by most analysts. The Microsoft Corporation generated $32,471.00 million in revenue during the last quarter, which is slightly lower than the $32,512.20 million predicted by analysts. In the second quarter last year, the firm recorded $1.14 earnings per share. Compared to the same quarter last year, the firmâ€™s revenue was down by -3.64%. Microsoft Corporation has the potential to record 4.30 EPS for the current fiscal year, according to equities analysts.

Investment analysts at Piper Jaffray published a research note on February 28th, 2019 where it informed investors and clients that Novavax, Inc. (NASDAQ:NVAX) is now rated as Underweight. Their price target on the stock stands at $0.25. Nomura also rated NVAX as Reiterated on January 31st, 2019, with its price target of $113 suggesting that NVAX could surge by 63.7% from its current share price. Even though the stock has been trading at $0.55/share, analysts expect it to surge higher by -3.17% to reach $1.46/share. It started the day trading at $0.548 and traded between $0.5201 and $0.53 throughout the trading session.

A look at its technical shows that NVAXâ€™s 50-day SMA is 1.03 while its 200-day SMA stands at 1.57. At the moment, only of Novavax, Inc. shares were sold short. The companyâ€™s average trading volume currently stands at 16.85M shares, which means that the short-interest ratio is just 5.61 days. Over the past seven days, the company moved, with its shift of -7.03%. Looking further, the stock has dropped -74.61% over the past 90 days while it lost -72.78% over the last six months.

The change in the stockâ€™s fortunes has led to several institutional investors altering their holdings of the stock. BlackRock Fund Advisors bought more NVAX shares, increasing its portfolio by +0.12% during the last quarter. This move now sees BlackRock Fund Advisors purchasing 35,337 shares in the last quarter, thus it now holds 29,473,014 shares of NVAX, with a total valuation of $16,239,631. The Vanguard Group Inc meanwhile sold more NVAX shares in the recently filed quarter, changing its stake to $11,381,471 worth of shares. SSgA Funds Management Inc followed the path by decreasing its NVAX portfolio by -15.30% in the quarter. This means that SSgA Funds Management Inc sold -2,658,231 shares in the last quarter and now controls 14,719,594 shares of the NVAX stock, with the valuation hitting $8,110,496.

Similarly, Geode Capital Management LLC increased its Novavax, Inc. shares by +9.72% during the recently filed quarter. After buying 452,163 shares in the last quarter, the firm now controls 5,106,122 shares of Novavax, Inc. which are valued at $2,813,473. In the same vein, Baker Bros Advisors LP decreased its Novavax, Inc. shares by during the most recent reported quarter. The firm sold 0 shares during the quarter which decreased its stakes to 4,718,318 shares and is now valued at $2,599,793. Following these latest developments, around 0.95% of Novavax, Inc. stocks are owned by institutional investors and hedge funds.

Let's block ads! (Why?)